SkinBioTherapeutics (LON:SBTX) Trading Down 34.6% – What’s Next?

SkinBioTherapeutics plc (LON:SBTX) fell 34.6% on Friday . The stock traded as low as GBX 6.25 and last traded at GBX 6.28. 360,278 shares traded hands during trading, a decline of 93% from the average session volume of 4,816,163 shares. The stock had previously closed at GBX 9.60.

SkinBioTherapeutics Trading Down 32.3%

The firm has a market cap of £16.84 million, a P/E ratio of -20.96 and a beta of 0.47. The stock has a 50 day simple moving average of GBX 14.06 and a 200-day simple moving average of GBX 15.01. The company has a current ratio of 4.84, a quick ratio of 10.01 and a debt-to-equity ratio of 10.55.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.